Skip to main content
. 2021 Aug 6;9(8):874. doi: 10.3390/vaccines9080874

Figure 9.

Figure 9

(A) Endpoint titers of SARS-CoV-2 spike-specific total IgG analyzed at weeks 2, 4, and 6 in mice immunized intramuscularly with naked pCMVkan-S (IM-naked), pCMVkan-S formulated with DOTAP4 at N/P ratios of 1:1 and 0.25:1, and by using electroporation device (IM-EP), (B) IgG subclass analysis; IgG1 and IgG2a in immunized mice sera collected on week 6. Data presented as mean ± SD of the endpoint titers in each vaccination group (n = 5). ** indicate p < 0.01 when compared to other groups. ns: not statistically significant.